Biosynex SA (EPA:ALBIO)

Biosynex Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-43.33	-36.95	15.66	104	31.37
Depreciation & Amortization	5.37	12.2	21.36	2.04	7.25
Other Amortization	7.31	-	-	-	-
Loss (Gain) From Sale of Assets	0.57	-0.02	-0.01	0.03	0
Asset Writedown & Restructuring Costs	8.8	1.26	-	-	-
Other Operating Activities	-1.74	-0.66	5.19	3.18	0.2
Change in Other Net Operating Assets	12.9	14.51	-37.26	0.58	-7.18
Operating Cash Flow	-10.12	-9.65	4.95	109.83	31.64
Operating Cash Flow Growth	-	-	-95.50%	247.17%	-
Capital Expenditures	-4.84	-39.54	-37.77	-19.02	-9.12
Sale of Property, Plant & Equipment	1.25	0.08	0.05	0.04	1.19
Cash Acquisitions	-1.01	-16.05	-9.74	-10.96	-
Other Investing Activities	-	0.71	0.69	0.97	-
Investing Cash Flow	-4.6	-54.81	-46.77	-28.96	-7.93
Long-Term Debt Issued	0.16	22.41	17.66	24.25	7.26
Long-Term Debt Repaid	-4.25	-14.83	-5.57	-7.42	-1.25
Net Debt Issued (Repaid)	-4.09	7.58	12.09	16.83	6.01
Issuance of Common Stock	-	-	-	19.43	4.45
Repurchase of Common Stock	-	-3.22	-1.73	-20.08	-
Common Dividends Paid	-	-	-20.44	-1.94	-
Other Financing Activities	3.29	0.81	-0.73	0.16	0.15
Financing Cash Flow	-0.8	5.17	-10.81	14.4	10.62
Miscellaneous Cash Flow Adjustments	-	-	0	-	-
Net Cash Flow	-15.52	-59.3	-52.64	95.27	34.33
Free Cash Flow	-14.96	-49.2	-32.83	90.82	22.52
Free Cash Flow Growth	-	-	-	303.29%	-
Free Cash Flow Margin	-14.79%	-52.91%	-16.70%	23.74%	14.63%
Free Cash Flow Per Share	-1.39	-4.59	-3.19	8.74	2.53
Levered Free Cash Flow	1.48	-42.49	-26.31	72.74	26.9
Unlevered Free Cash Flow	3.32	-41.19	-26	72.96	27.04
Change in Working Capital	12.9	14.51	-37.26	0.58	-7.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.